Harbin Pharmaceutical Group (600664.SH): The dextrose benzene sulfonate benzoate tablets produced by Harbin Pharmaceutical Group Factory Six have been discontinued in 2018. The related reports have confused the trademark name with the drug name.

Harbin Pharmaceutical Group (600664.SH) announced that the company has noticed reports in some media that "Diacetolol is 'halted'" and "'Diacetolol' is completely banned for sale". Recently, the official website of the National Medical Products Administration announced the cancellation of the registration certificate for diphenhydramine tablets, halting the production, sales, and use of diphenhydramine tablets in China, and canceling the registration certificate for the drug. Some media reports claim that diphenhydramine tablets are commonly known as "Diacetolol". The company clarifies the following: The company's subsidiary Harbin Pharmaceutical Group Pharmaceutical Factory No. 6 (referred to as "Harbin Pharmaceutical Factory No. 6") had a registration approval for "diphenhydramine tablets" in the past, but the product was discontinued in 2018. In 2020, the company did not apply for re-registration and the approval document has been invalidated. The list of 80 cancelled approval numbers for diphenhydramine tablets in the attachment variety information table of the "Announcement of the National Medical Products Administration on the Cancellation of the Registration Certificate for Diphenhydramine Tablets" (2025 No. 2) does not include the company's product. The company owns the trademark "Xieliting", which is a trademark registered and approved for use by the National Intellectual Property Office. The cancellation announced by the National Medical Products Administration this time is for the registration certificate of diphenhydramine tablets, not the "Xieliting" trademark. Currently, the "Xieliting" trademark is being used normally, products bearing this trademark are being sold normally, and there are no diphenhydramine tablets products under this trademark. Online reports are confusing the trademark name with the drug name, causing certain misleading information to the general investors.